The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma

Xiaoxiao Hao*, Xiaolei Wei*, Fen Huang, Yongqiang Wei, Hong Zeng, Linwei Xu, Qinjun Zhou, Ru Feng*

Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

☯ These authors contributed equally to this work.

* ruth1626@hotmail.com

Abstract

The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL) remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL. Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%). The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67 overexpression ($p < 0.05$). Patients with CD30 expression showed significantly poor overall and event-free survival compared with CD30 negative patients ($p = 0.031$ and $0.041$, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI) ($p = 0.001$ and $0.007$, respectively). The prognostic value of CD30 expression retained in DLBCL patients treated with either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CHOP (rituximab+CHOP). The multivariate analysis revealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival ($p = 0.001$ and $0.002$, respectively). In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCB DLBCL. The expression of CD30 implied poor outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.

Introduction

Diffuse large B-cell lymphoma (DLBCL), characterized by a high degree of heterogeneity in immunophenotype, pathogenetics, and clinical response, is the most common type of non-Hodgkin lymphoma (NHL) [1]. The introduction of rituximab in immunochemotherapy has dramatically improved the outcome of patients with DLBCL [2–4]. Still, approximately 40% of
patients with DLBCL suffer relapse and eventually die due to the disease [5], which highlights the need to construct prognostic models that can guide risk-justified treatment selection. International prognostic index (IPI) remains a valuable tool for risk stratification of DLBCL patients in the rituximab era [6, 7]. However it does not identify individual patients who will suffer a particularly aggressive clinical course, given that these patients can be found in the same subgroup. These prognostic variables are considered to be proxies for the underlying cellular and molecular variation within DLBCL.

CD30, a 120-kd transmembrane cytokine receptor of the tumor necrosis factor receptor (TNFR) family, is an important immune marker for the diagnosis of classical Hodgkin Lymphoma and anaplastic large cell lymphoma and carry a favorable prognosis[8, 9]. Recent results indicate that CD30 expression had high prognostic relevance to the clinical outcome of DLBCL patients treated with the R-CHOP chemotherapy regimen [10, 11]. However, the prognostic value of CD30 expression in DLBCL has been controversial and it still remains unknown whether the prognostic value of CD30 expression can be applied to all the therapeutic regimens and, most importantly, if it can improve the prognostic profile based on the IPI. Therefore we performed this study to explore the prognostic value of CD30 expression in DLBCL patients with different treatment and whether CD30 expression has an independent prognostic value when compared with the IPI at diagnosis.

**Patients and Methods**

**Patient population**

All 146 patients consecutively diagnosed as de novo DLBCL with the available CD30 expression status in Nanfang Hospital between January, 2006 and February, 2013 were further confirmed according to WHO classification. Patients were excluded if they were HIV-positive, or had various other types of DLBCL, including primary mediastinal, central nervous system, intravascular and testicular lymphomas, transformed NHL and posttransplant lymphoproliferative disorder. All patients were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). This study was approved by the Ethics Committee of Southern Medical University affiliated Nanfang Hospital. All patients had provided written informed consent themselves or their guardians prior to treatment allowing the use of their medical records for medical research.

**Immunohistochemistry (IHC)**

The specimens from formalin-fixed and paraffin-embedded samples at the time of initial diagnosis were collected for histological review and immunohistochemical analysis. IHC was carried out using a peroxidase-conjugated labeled dextran polymer method as our previously described[12]. Rabbit monoclonal antibody for CD30 (clone EP154, 1:50 dilution) was from ZSGB-BIO, Beijing, China. The other markers assessed in the present study included CD10, BCL-6, MUM-1, BCL-2 and Ki-67 (ZSGB-BIO, Beijing). EBV was detected by in situ hybridization technique using a fluorescein-conjugated EBER oligonucleotide probe (Leica, America). A total of 200 cells in 5 well-preserved areas were scored for overall staining intensity and the percentage of the positively stained cells. All the slides were reviewed blindly by two experienced pathologists, with discrepant cases being jointly reviewed by a multihead microscope. CD30 and EBV staining in more than 20% of the malignant cells were considered positive, as previously described [10, 11, 13]. The cases were considered positive if 30% or more of the tumor cells were stained with CD10, BCL6, MUM1 and BCL-2. Ki67 staining in more than 85% of the malignant cells was considered overexpression as previous study [14]. Germinal center B-cell-like
(GCB) and non-germinal center B-cell-like (Non-GCB) DLBCL were classified according to the algorithm described by Hans et al [15].

**Statistical analysis**

Distributions of variables between the different groups were carried out by Mann-Whitney. Overall survival (OS) and event-free survival (EFS) were analyzed by Kaplan-Meier method and compared by the log-rank test. OS was defined from the time of diagnosis to the date of any cause to death or last follow-up[16]. EFS was defined from the time of diagnosis to the date of relapse, progression, death or last follow-up[16]. Univariate and multivariate analyses were assessed by Cox proportional hazard regression model. Factors found to be significant in the univariate analysis were included in the multivariate analysis. All p values were two-sided and the significance was defined as $p<0.05$. Data were analyzed by the Statistical Package for Social Sciences 13.0.

**Results**

**Patients’ characteristics**

Of these 146 patients included, fifty-two patients were women and the ratio of male-to-female was 1.81:1. The median age was 49 years old (ranged 15 to 82 years), which is similar to three other recent studies of Chinese DLBCL patients [17–19], but much younger than those reported for DLBCL populations in the Western countries [20, 21]. Thirty-four patients (23.3%) were >60 years and 90 patients (61.6%) were in advanced stage (stages III and IV). Fifty-five patients had B symptoms and Eighty-eight (59.3%) had an elevated lactate dehydrogenase (LDH). Based on the IPI, 80 patients (55.0%) were in the low/low intermediate group. Sixty-two patients were treated with CHOP and others treated with R-CHOP. Baseline clinical features at the time of diagnosis are listed in Table 1.

**The expression and prognosis of CD30 in DLBCL**

We reviewed CD30 expression in a total of 146 de novo DLBCL cases and found 15.7% (23/146) of DLBCL patients were positive (S1 Fig). BCL-2 and Ki-67 overexpression were detected in 63.5% and 73.6% of all patients. EBV was detected in 4.1% (6/146) of all patients. CD30 positive cases had a higher incidence of B symptoms ($p = 0.001$), bone marrow involvement ($p<0.001$), BCL-2 and Ki-67 overexpression ($p = 0.041$ and 0.048, respectively). The other clinical characteristics including age ($p = 0.849$), gender ($p = 0.573$), LDH ($p = 0.389$), performance status ($p = 0.489$), Ann Arbor stage ($p = 0.396$), extranodal sites ($p = 0.608$) and IPI ($p = 0.466$) showed no significant differences in DLBCL patients with and without the expression of CD30.

According to the Hans’ algorithm the GCB DLBCL was applied to 50 of 146 cases (34.2%), the other 96 were of the Non-GCB DLBCLs. CD30 is expressed predominantly in Non-GCB DLBCL ($p = 0.020$).

After EBV-positive cases were excluded, patients with CD30 expression showed significantly inferior OS and EFS compared with CD30-negative patients (Fig 1). The 5-year OS was 19.1% in patients with CD30 expression versus 58.5% for patients without CD30 expression ($p = 0.031$). The 5-year EFS was 12.9% for CD30-positive patients versus 58.4% for CD30-negative patients ($p = 0.041$). Furthermore, in the high intermediate/high group, patients with CD30 expression implied a poor OS and EFS (not reached versus 42.9% of 5-year OS, $p = 0.001$; not reached versus 32.1% of 5-year EFS, $p = 0.007$, Fig 2A and 2B), while no significant difference was observed in the low/low intermediate group (44.5% versus 73.4% of 5-year OS, $p = 0.929$; 25.4% versus 68.5% of 5-year EFS, $p = 0.411$, Fig 2C and 2D). All patients were
Table 1. Clinical characteristics of patients according to CD30 expression.

| Characteristics          | Total   | Negative | Positive | P-value |
|--------------------------|---------|----------|----------|---------|
| Age                      |         |          |          |         |
| ≤60y                      | 112(76.7%) | 94(76.4%) | 18(78.3%) | 0.849   |
| >60y                      | 34(23.3%)  | 29(23.6%)  | 5(21.7%)  |         |
| Gender                   |         |          |          |         |
| Female                   | 52(35.6%) | 45(36.6%) | 7(20.4%)  | 0.573   |
| Male                     | 94(64.4%) | 78(63.4%) | 16(69.6%) |         |
| Performance status       |         |          |          |         |
| 0–1                      | 104(71.4%) | 89(72.4%) | 15(65.2%) | 0.489   |
| 2–4                      | 42(28.6%)  | 34(27.6%)  | 8(34.8%)  |         |
| B symptoms               |         |          |          |         |
| No                       | 85(60.7%) | 79(66.4%) | 6(28.6%)  | 0.001   |
| Yes                      | 55(39.3%) | 40(33.6%) | 15(71.4%) |         |
| Extranodal sites         |         |          |          |         |
| 0–1                      | 77(52.7%) | 66(53.7%) | 11(47.8%) | 0.608   |
| ≥2                       | 69(47.3%) | 57(46.3%) | 12(52.2%) |         |
| Ann Arbor stage          |         |          |          |         |
| I/II                     | 56(38.4%) | 49(39.8%) | 7(30.4%)  | 0.396   |
| III/IV                   | 90(61.6%) | 74(60.2%) | 16(69.6%) |         |
| LDH                      |         |          |          |         |
| Normal                   | 58(40.7%) | 47(38.2%) | 11(47.8%) | 0.389   |
| Elevated                 | 88(59.3%) | 76(61.8%) | 12(52.2%) |         |
| BM involvement           |         |          |          | <0.001  |
| No                       | 120(82.2%) | 107(87.0%) | 13(56.5%) |         |
| Yes                      | 26(17.8%) | 16(13.0%)  | 10(43.5%) |         |
| IPI                      |         |          |          |         |
| 0–2                      | 80(55.0%) | 69(56.1%) | 11(47.8%) | 0.466   |
| 3–5                      | 66(45.0%) | 54(43.9%) | 12(52.2%) |         |
| COO                      |         |          |          |         |
| GCB                      | 50(34.2%) | 47(38.2%) | 3(13.0%)  | 0.020   |
| Non-GCB                  | 96(65.6%) | 76(61.8%) | 20(80%)   |         |
| BCL-2                    |         |          |          |         |
| negative                 | 42(36.5%) | 39(40.6%) | 3(15.8%)  | 0.041   |
| positive                 | 73(63.5%) | 57(59.4%) | 16(84.2%) |         |
| Ki-67                    |         |          |          | 0.048   |
| Negative                 | 34(26.4%) | 30(27.8%) | 4(19.0%)  |         |
| Positive                 | 95(73.6%) | 78(72.2%) | 17(81.0%) |         |

LDH, Lactate dehydrogenase; BM, bone marrow; IPI, international prognostic index.
COO, cell of origin; GCB, germinal center B-cell like.

doi:10.1371/journal.pone.0126615.t001

divided into CHOP and R-CHOP group according to treatment. In the patients treated with CHOP, CD30 expression also showed a trend to predict poor for OS and EFS (not reached versus 40.9% of 5-year OS, \( p = 0.019 \); not reached versus 32.0% of 5-year EFS, \( p = 0.050 \), Fig 3A and 3B). In the R-CHOP group, CD30 expression was still associated with a shorter OS and
EFS as compared with CD30-negative patients (23.9% versus 74.4% of 5-year OS, \( p = 0.039 \); 15.2% versus 66.5% of 5-year EFS, \( p = 0.048 \), Fig 3C and 3D).

Multivariate analysis including all the significant factors in the univariate analysis showed that CD30 expression independent of LDH and B symptoms was an inferior predictor for OS (HR = 4.710; 95% CI = 1.964–11.295, \( p = 0.001 \)) and EFS (HR = 3.393; 95% CI = 1.560–7.380, \( p = 0.002 \)). The multivariate survival analysis was shown in Table 2.

Discussion

In the present study, we evaluated the clinical impact of CD30 expression in a cohort of patients with de novo DLBCL. The expression of CD30 was associated with a shorter OS and EFS in DLBCL patients treated with either CHOP or R-CHOP. Multivariate analysis revealed that the expression of CD30 retained an independent predictive factor associated with poor OS and EFS in patients with DLBCL. However, CD30 only added statistically significant prognostic information in the high intermediate/high-risk IPI patients, but not in the low/low intermediate-risk IPI group.

Due to factors including difficulties in the standardization of the IHC staining method and evaluation of the results, there has been a wide range of reported incidence of CD30 (9.6% to 21%) among DLBCL samples[10, 11, 22]. In our study, approximately 15.7% of the DLBCL patients were classified as CD30-positive using 20% as a cut-off value in our study. The CD30-positive patients showed a greater tendency toward the presence of symptoms, bone marrow involvement and Ki-67 overexpression. Previous study has showed that CD30 expression on normal cells is restricted to activated T and B lymphocytes[23–25] as well as the activated B cell-like (ABC) DLBCL has more frequent and higher CD30 mRNA expression compared with GCB-DLBCL[26]. DLBCL has been divided into germinal center B cell–like (GCB) and activated B cell–like (ABC) subtypes by gene expression profiling with different clinical outcome[26]. Due to a small panel of IHC stains not completely capturing information obtained from GFP.
and the difference in the immunostaining methodologies and evaluation of the results, the study on IHC-based algorithms predicting GEP analysis are controversial\[27\]. Despite these limitations, Hans’ algorithm with a high correlation with GEP results has been widely used in clinical practice\[15\]. In our study, 50 of 146 cases were categorized into the GC subtype and the other 96 were the non-GC subtype based on Hans’ algorithm. It is also interesting to note that CD30 expression was predominant in Non-GCB DLBCL described by Hans’ algorithm and correlated with the expression of bcl-2 protein in this study, which may contribute to explain the poor outcome. When CD30 expression, Non-GCB DLBCL and bcl-2 overexpression were included in the multivariate analysis by Cox modeling, CD30 expression didn’t retain its
prognostic value (Data was not shown). So CD30 expression may be an useful treatment target in Non-GCB DLBCL patients distinguishing from GCB DLBCL.

The CD30 protein belongs to a large family of the TNFR superfamily[23]. The pleiotropic effects of CD30 signaling on tumor cells varies from enhanced proliferation and survival to induction of growth inhibition and cell death, mainly through activation of the nuclear translocation of members of the NF-κB transcription factor family and mitogen activated protein kinase (MAPK) pathways[28]. The various reports on CD30 expression as a prognostic marker in DLBCL treated with R-CHOP have been contradictory[10, 11, 29]. Furthermore, the introduction of rituximab to chemotherapy has remarkably improved the survival and altered the predictive values of known prognostic factors in DLBCL[30, 31]. Our datasuggested that CD30 expression was associated with poor survival in DLBCL patients treated with either
CHOP or R-CHOP. The further results of subgroup analysis combing CD30 and IPI showed that CD30 expression could identify a subgroup of DLBCL patients with inferior clinical outcome from high intermediate/high-risk IPI subgroup. A recent study from Collie et al. [11] showed that CD30 expression is a predictive factor of poor survival in DLBCL patients treated with R-CHOP, in agreement with our finding. However, another study in a large cohort of de novo DLBCL patients revealed that CD30 expression could identify a superior clinical outcome subgroup of DLBCL patients [10]. Variable results among studies may result from different antibodies, IHC staining/scoring method, sample sizes and the heterogeneity of patients. In the present report there has a high proportion (76.7%) of patients who were >60 years old and the expression of CD30 in patients >60 years old implied a poor survival, but not in patients <60 years (S2 Fig), which may cause the difference between the studies.

However, it should be noted that this study was a retrospective analysis based on a relatively small numbers of patients. The choice of patients might have been biased, and other unrecognized bias might have influenced the results. Therefore, these findings need to be confirmed by future prospective study of larger cohorts. To minimize the inherent biases of the study, we selected only patients with de novo DLBCL treated with standard first-line chemotherapy and excluded other presentations of DLBCL such as HIV-positive, primary mediastinal, central nervous system, intravascular and testicular lymphomas, transformed NHL and posttransplant lymphoproliferative disorder.

In summary, we have studied the expression of CD30 in an independent cohort of de novo DLBCL and found that CD30 expression was predominant in Non-GCB DLBCL. The expression of CD30 detected by IHC seems to be associated with an inferior clinical outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, who may benefit from experimental therapies such as anti-CD30 monoclonal antibody.

### Table 2. Multivariate Cox regression analysis for survival.

| Prognostic factors       | HR    | 95%CI            | P-value |
|--------------------------|-------|-----------------|---------|
| CD30 positive            | 4.710 | 1.964–11.295    | 0.001   |
| LDH elevated             | 5.842 | 1.939–17.603    | 0.002   |
| B Symptoms               | 2.292 | 1.044–5.034     | 0.039   |
| Performance status 3–4   | 0.813 | 0.368–1.795     | 0.608   |
| Extranodal sites ≥2      | 1.306 | 0.421–4.047     | 0.644   |
| IPI 3–5                  | 1.561 | 0.405–6.022     | 0.518   |

**Event-free survival**

| Prognostic factors       | HR    | 95%CI            | P-value |
|--------------------------|-------|-----------------|---------|
| CD30 positive            | 3.393 | 1.560–7.380     | 0.002   |
| LDH elevated             | 3.431 | 1.469–8.016     | 0.004   |
| B Symptoms               | 1.665 | 0.898–3.086     | 0.106   |
| Bone marrow involvement  | 1.472 | 0.798–2.716     | 0.216   |
| Extranodal sites ≥2      | 1.265 | 0.459–3.143     | 0.709   |
| Ann Stage III–IV         | 1.628 | 0.614–4.317     | 0.328   |
| IPI 3–5                  | 1.177 | 0.434–3.198     | 0.749   |

LDH, Lactate dehydrogenase; IPI, International Prognostic Index; HR, hazard ratio; 95%CI, 95% confidence interval.

doi:10.1371/journal.pone.0126615.t002
Supporting Information

S1 Fig. Representative images of CD30 expression in patients with DLBCL. (A) CD30 staining in a negative case. (B) CD30 staining in a positive case (×400).

S2 Fig. Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and age. OS (A) and EFS (B) according to CD30 expression in DLBCL patients ≤60 years. OS (C) and EFS (D) according to CD30 expression in DLBCL patients >60 years.

Acknowledgments

RF and XLW designed the study, analyzed and interpreted the data. XXH and XLW collected and analyzed data. YQW, FH and HZ collected data. XXH, LWX and QJZ retrieved and reviewed the expression of CD30 in the samples. RF, XLW and XXH wrote the manuscript. All authors read and approved the final manuscript. This work was supported by the Science and Technology Project of Guangdong Province (Grant No. 2010B050700020), the Science and Technology Project of Guangzhou City (Grant No. 12C22121553) and the Natural Science Foundation of Guangdong Province (Grant No. S2011010003790).

Author Contributions

Conceived and designed the experiments: RF XLW. Analyzed the data: RF XLW XXH YQW FH HZ. Wrote the paper: RF XLW XXH. Retrieved and reviewed the expression of CD30 in the samples: XXH LWX QJZ. Read and approved the final manuscript: RF XLW XXH YQW FH HZ LWX QJZ.

References

1. Swerdlow SH CE, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (4th Ed). Lyon, France: IARC. 2008.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England journal of medicine. 2002; 346(4):235–42. Epub 2002/01/25. doi:10.1056/NEJMoa011795 PMID: 11807147.
3. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Tmeny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The lancet oncology. 2006; 7(5):379–91. Epub 2006/05/02. doi:10.1016/s1470-2045(06)70664-7 PMID: 16648042.
4. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(19):3121–7. Epub 2006/06/07. doi: 10.1200/jco.2005.05.1003 PMID: 16754935.
5. Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012:402–9. Epub 2012/12/13. doi: 10.1182/asheducation-2012.1.402 PMID: 23233611.
6. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109(5):1857–61. Epub 2006/11/16. doi: 10.1182/blood-2006-08-038257 PMID: 17105812.
7. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. Journal of clinical oncology: official journal of the American Society of
CD30 Expression in DLBCL

Clinical Oncology. 2010; 28(14):2373–80. Epub 2010/04/14. doi: 10.1200/JCO.2009.26.2493 PMID: 20385988.

8. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995; 85(1):1–14. Epub 1995/01/01. PMID: 7803786.

9. Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leukemia & lymphoma. 2011; 52(9):1641–54. Epub 2011/05/31. doi: 10.3109/10428194.2011.574761 PMID: 21619423.

10. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013; 121(14):2715–24. Epub 2013/01/25. doi: 10.1182/blood-2012-10-461848 PMID: 23343832; PubMed Central PMCID: PMCPMC3700465.

11. Collie Angela M. B., Hill Brian T., Manilich Elena A., Smith Mitchell R, Hsi Eric D.. CD30 Immunohistochemical Expression In Diffuse Large B-Cell Lymphoma Is Associated With Decreased Overall Survival and The Non-Germinial Center Molecular Subtype. Blood. 2013 122(21):4318–8.

12. Wei X, Huang F, Wei Y, Jing H, Xie M, Hao X, et al. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leukemia research. 2014. Epub 2014/04/10. doi: 10.1016/j.leukres.2014.03.013 PMID: 24713260.

13. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007; 110(3):972–8. Epub 2007/04/03. doi: 10.1182/blood-2007-01-067769 PMID: 17400912.

14. Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. European journal of haematology. 2010; 85(2):149–57. Epub 2010/05/19. doi: 10.1111/j.1600-0609.2010.01467.x PMID: 20477862.

15. Hans CP, Weisenburger DD, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275–82. Epub 2003/09/25. doi: 10.1182/blood-2003-05-1545 PMID: 14504078.

16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(5):579–86. Epub 2007/01/24. doi: 10.1200/jco.2006.09.2403 PMID: 17242396.

17. Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Annals of hematology. 2014. Epub 2014/08/03. doi: 10.1007/s00277-014-2167-0 PMID: 25083376.

18. Jin X, Ding H, Ding N, Fu Z, Song Y, Zhu J. Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. Journal of hematology & oncology. 2012; 5:51. Epub 2012/08/18. doi: 10.1186/1756-8722-5-51 PMID: 22897949; PubMed Central PMCID: PMCPMC3467177.

19. Zhou D, Xie WZ, Hu KY, Huang WJ, Wei GO, He JS, et al. Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases. Asian Pacific journal of cancer prevention: APJCP. 2013; 14(2):929–34. Epub 2013/04/30. PMID: 23621263.

20. Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(11):1452–7. Epub 2011/03/09. doi: 10.1200/jco.2010.33.3419 PMID: 21383296.

21. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(24):7785–95. Epub 2011/09/22. doi: 10.1158/1078-0432.rcr-11-0287 PMID: 21933893.

22. Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, Chapman-Fredricks JR. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leukemia & lymphoma. 2013; 54(11):2405–11. Epub 2013/02/26. doi: 10.3109/10428194.2013.778407 PMID: 23432725.

23. Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Current opinion in pharmacology. 2004; 4(4):355–9. Epub 2004/07/15. doi: 10.1016/j.coph.2004.02.007 PMID: 15251128.
24. Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. The Journal of pathology. 2000; 190(5):613–8. Epub 2000/03/23. doi:10.1002/(sici)1096-9896(200004)190:5<613::aid-path559>3.0.co;2-o PMID: 10727988.

25. de Leval L, Gaulard P. CD30+ lymphoproliferative disorders. Haematologica. 2010; 95(10):1627–30. Epub 2010/10/05. doi:10.3324/haematol.2010.029256 PMID: 20884717; PubMed Central PMCID: PMCPMC2948085.

26. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503–11. Epub 2000/02/17. doi:10.1038/35000501 PMID: 10676951.

27. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011; 117(18):4836–43. Epub 2011/03/29. doi:10.1182/blood-2010-12-322362 PMID: 21441466.

28. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994; 83(8):2045–56. Epub 1994/04/15. PMID: 8161776.

29. Gandhi Shipra, Neppalli Vishala T., Deeb George, Czuczman Myron S., Hernandez-Ilizaliturri FJ. Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2013; 122(21):5024.

30. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003; 101(11):4279–84. Epub 2003/02/11. doi: 10.1182/blood-2002-11-3442 PMID: 12576316.

31. Saito B, Shiozawa E, Usui T, Nakashima H, Maeda T, Hattori N, et al. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia. 2007; 21(12):2563–6. Epub 2007/06/29. doi: 10.1038/sj.leu.2404844 PMID: 17597802.